EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of pyrimidine nucleos(t)ide therapy in thymidine kinase 2 deficiency

Michio Hirano iD, Caterina Garone iD, Richard Haas, Carmen Paradas, Fernando Scaglia iD, Irene Rebollo Mesa iD, Carl Chiang iD, Anny-Odile Colson iD, Susan VanMeter iD, Cristina Domínguez-González iD

Brain Communications · 05.05.2026 · 8 (3)

DOI: 10.1093/braincomms/fcag201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain Communications, online erschienen am 03.06.2026. Verfasst von Michio Hirano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, H. Houston Merritt Center for Neuromuscular Disorders, Columbia University Irving Medical Center, New York, NY 10032, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, UCB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thymidine kinase 2 deficiency (TK2d) (MIM 609560) is an ultra-rare, autosomal recessive mitochondrial myopathy caused by TK2 variants, leading to mitochondrial DNA depletion and/or multiple deletions. People with thymidine kinase 2 deficiency experience progressive myopathy, bulbar weakness and respiratory insufficiency, often losing the ability to walk, eat and breathe independently. Doxecitine and doxribtimine represents the first approved treatment for patients with thymidine kinase 2 deficiency with age of symptom onset ≤12 years by the US Food and Drug Administration and the European Medicines Agency; previously, disease management was limited to supportive care. We investigated the efficacy and safety of pyrimidine nucleos(t)ide therapy in thymidine kinase 2 deficiency. Patients treated with pyrimidine nucleos(t)ides were pooled from retrospective (NCT03701568, NCT05017818) and prospective (NCT03845712) studies and company-supported Expanded Access Programs. Untreated patients were pooled from literature reviews and a retrospective chart review study (NCT05017818). Patient subgroups were stratified by age of thymidine kinase 2 deficiency symptom onset (≤12 years and >12 years). The primary outcome was survival in 50th-percentile matched pairs of treated and untreated patients. Other outcomes included status of developmental motor milestones, ventilatory and feeding tube support, and safety. In total, 218 patients were included (treated: 104; untreated: 114). Baseline demographics and characteristics were comparable between subgroups. Most patients had an age of symptom onset ≤12 years [treated: 82/104 (78.8%); untreated: 93/114 (81.6%)]. In the age-of-symptom-onset-≤12-years subgroup, restricted mean survival time (95% confidence interval) was 29.2 (28.2, 30.3) years over the 30 years after symptom onset for treated patients and 14.4 (11.1, 17.6) years for untreated patients. Loss of ≥1 acquired motor milestone was more frequent before treatment start than after. Substantially more patients regained ≥1 lost motor milestone after treatment start than before. Ventilatory and feeding support were used across all age-of-symptom-onset subgroups, but some patients reduced or discontinued support after starting treatment and fewer patients initiated support after treatment start than before. Most treatment-emergent adverse events (TEAEs) did not lead to discontinuation. The most frequent TEAE was diarrhoea [43/50 patients (86.0%)], which was generally mild or moderate and resolved with dose reduction. Serious TEAEs occurred in 28/50 patients (56.0%); few were considered to be drug related [4/50 (8.0%)]. In total, 3/67 patients (4.5%) experienced a fatal serious TEAE, which were not considered to be drug related. These findings indicate that pyrimidine nucleos(t)ide therapy improves survival and functional outcomes in people with thymidine kinase 2 deficiency, especially those with age of symptom onset ≤12 years, and has an acceptable safety profile.

Schlagwörter

Stichwörter der Autor:innen

mitochondrial myopathypyrimidine nucleos(t)ide therapysurvivalthymidine kinase 2 deficiencytreatment efficacy

Autor:innen und Institutionen

  • Department of Neurology, H. Houston Merritt Center for Neuromuscular Disorders, Columbia University Irving Medical Center, New York, NY 10032, USA.
  • Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna 40138, Italy.
  • IRCCS Istituto delle Scienze Neurologiche, UOC Neuropsichiatria dell'età Pediatrica di Bologna, Bologna 40139, Italy.
  • Department of Neurosciences, University of California San Diego and Rady Children's Hospital, San Diego, CA 92093, USA.
  • Neurology Department, Neuromuscular Disorders Unit, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Consejo Superior de Investigaciones Científicas, University of Seville, Seville 41013, Sp…
  • Center for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid 28029, Spain.

ORCID-Profile: Michio Hirano, Caterina Garone, Fernando Scaglia, Irene Rebollo Mesa, Carl Chiang, Anny-Odile Colson, Susan VanMeter, Cristina Domínguez-González

Förderung

  • NINDS NIH HHS
  • UCB

Zitieren

APA

Hirano, M., Garone, C., Haas, R., Paradas, C., Scaglia, F., Rebollo Mesa, I., Chiang, C., Colson, A. O., VanMeter, S., & Domínguez-González, C. (2026). Efficacy and safety of pyrimidine nucleos(t)ide therapy in thymidine kinase 2 deficiency. Brain Communications, 8(3). https://doi.org/10.1093/braincomms/fcag201

Vancouver

Hirano M, Garone C, Haas R, Paradas C, Scaglia F, Rebollo Mesa I, et al. Efficacy and safety of pyrimidine nucleos(t)ide therapy in thymidine kinase 2 deficiency. Brain Communications. 2026;8(3). doi:10.1093/braincomms/fcag201

BibTeX
@article{Hirano2026,
  author = {Hirano, Michio and Garone, Caterina and Haas, Richard and Paradas, Carmen and Scaglia, Fernando and Rebollo Mesa, Irene and Chiang, Carl and Colson, Anny-Odile and VanMeter, Susan and Domínguez-González, Cristina},
  title = {Efficacy and safety of pyrimidine nucleos(t)ide therapy in thymidine kinase 2 deficiency},
  journal = {Brain Communications},
  year = {2026},
  volume = {8},
  number = {3},
  doi = {10.1093/braincomms/fcag201}
}
Kostenlos starten →